Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg starts coverage of Mortgage Advice Bureau at 'buy'

(Sharecast News) - Berenberg initiated coverage of Mortgage Advice Bureau on Tuesday with a 'buy' rating and 1,150p price target. It said the company has grown into one of the UK's leading platforms for mortgage intermediaries, with links to close to 200 appointed representative (AR) firms and approximately 2,000 advisers.

"The company has significantly outperformed broader mortgage market trends over the past decade and is well positioned to benefit as underlying mortgage market volumes recover through FY25-FY26," Berenberg said.

"In addition, a notable focus on improving the company's technological capabilities should help to improve the competitive position of the firm and its profitability dynamics."

The bank also said that MAB's balance sheet has been in a strong position since listing in 2014 and it expects it to remain so.

"Management is targeting cash conversion above 100% in the medium term, supported by: a low level of capex; a negative working capital cycle; and a low level of exceptional items and other distorting factors," it said.

"We expect selective M&A to feature in the medium-term strategic story."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.